The Aporia
Cox, A. (2026, November 3). TGA clears weight loss tablets for use in Australia. ABC News (AU). https://www.abc.net.au/news/2026-11-03/weight-loss-tablet-cleared-for-use-in-australia/107343340
Cox, Anna. “TGA clears weight loss tablets for use in Australia.” ABC News (AU), 3 Nov. 2026, https://www.abc.net.au/news/2026-11-03/weight-loss-tablet-cleared-for-use-in-australia/107343340.
Cox, Anna. “TGA clears weight loss tablets for use in Australia.” ABC News (AU), November 3, 2026. https://www.abc.net.au/news/2026-11-03/weight-loss-tablet-cleared-for-use-in-australia/107343340.
Dated from the outlet's own feed. Check the original for its byline.
As of November 3, 2026, the Therapeutic Goods Administration (TGA) has approved Wegovy, a daily weight loss tablet manufactured by Novo Nordisk, for use in Australia. This makes it the first GLP-1 (glucagon-like peptide-1) medication to be cleared for oral consumption in the country. Previously, Australians could only access GLP-1 drugs through weekly injections.
Sales of GLP-1 medications have surged in recent years; a University of New South Wales study found that usage increased almost tenfold from about 58,000 units in May 2020 to approximately 500,000 sales by April 2025. The TGA's approval is expected to further boost demand for these medications, with the oral pill set to hit the market by the end of the year.
However, concerns have been raised about potential risks associated with increased prescribing, including hospitalizations of patients with eating disorders and warnings from the TGA regarding links between GLP-1 drugs and suicidal thoughts.